451 related articles for article (PubMed ID: 32562659)
21. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
The NAMS 2020 GSM Position Statement Editorial Panel
Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449
[TBL] [Abstract][Full Text] [Related]
22. Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes.
Sokol ER; Karram MM
Menopause; 2017 Jul; 24(7):810-814. PubMed ID: 28169913
[TBL] [Abstract][Full Text] [Related]
23. CO2-Laser therapy and Genitourinary Syndrome of Menopause: A Systematic Review and Meta-Analysis.
Filippini M; Porcari I; Ruffolo AF; Casiraghi A; Farinelli M; Uccella S; Franchi M; Candiani M; Salvatore S
J Sex Med; 2022 Mar; 19(3):452-470. PubMed ID: 35101378
[TBL] [Abstract][Full Text] [Related]
24. Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause.
Archer DF; Simon JA; Portman DJ; Goldstein SR; Goldstein I
Expert Rev Endocrinol Metab; 2019 Sep; 14(5):301-314. PubMed ID: 31526199
[No Abstract] [Full Text] [Related]
25. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
DeGregorio MW; Zerbe RL; Wurz GT
Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
[TBL] [Abstract][Full Text] [Related]
26. Rationale and design for fractional microablative CO
Flint R; Cardozo L; Grigoriadis T; Rantell A; Pitsouni E; Athanasiou S
Climacteric; 2019 Jun; 22(3):307-311. PubMed ID: 30676818
[TBL] [Abstract][Full Text] [Related]
27. Laser therapy for the restoration of vaginal function.
Gambacciani M; Palacios S
Maturitas; 2017 May; 99():10-15. PubMed ID: 28364861
[TBL] [Abstract][Full Text] [Related]
28. Sexual Function in Women Suffering From Genitourinary Syndrome of Menopause Treated With Fractionated CO
Salvatore S; Pitsouni E; Del Deo F; Parma M; Athanasiou S; Candiani M
Sex Med Rev; 2017 Oct; 5(4):486-494. PubMed ID: 28843942
[TBL] [Abstract][Full Text] [Related]
29. Ospemifene in the treatment of vulvovaginal atrophy.
Barnes KN; Pearce EF; Yancey AM; Forinash AB
Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
[TBL] [Abstract][Full Text] [Related]
30. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy.
Crean-Tate KK; Faubion SS; Pederson HJ; Vencill JA; Batur P
Am J Obstet Gynecol; 2020 Feb; 222(2):103-113. PubMed ID: 31473229
[TBL] [Abstract][Full Text] [Related]
31. Microablative fractional CO
Pitsouni E; Grigoriadis T; Tsiveleka A; Zacharakis D; Salvatore S; Athanasiou S
Maturitas; 2016 Dec; 94():131-136. PubMed ID: 27823733
[TBL] [Abstract][Full Text] [Related]
32. The effect of CO
Latul YP; Vodegel EV; Kastelein AW; Alkemade L; Ras L; Hilty MP; Favaron E; Ince Y; Ince C; Jeffery S; Guler Z; Roovers JWR
Neurourol Urodyn; 2023 Aug; 42(6):1381-1389. PubMed ID: 37334848
[TBL] [Abstract][Full Text] [Related]
33. Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial.
Politano CA; Costa-Paiva L; Aguiar LB; Machado HC; Baccaro LF
Menopause; 2019 Aug; 26(8):833-840. PubMed ID: 31246661
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
[TBL] [Abstract][Full Text] [Related]
35. Fractional CO
Murina F; Karram M; Salvatore S; Felice R
J Sex Med; 2016 Dec; 13(12):1915-1917. PubMed ID: 27864031
[TBL] [Abstract][Full Text] [Related]
36. Fractional CO
Lang P; Dell JR; Rosen L; Weiss P; Karram M
Lasers Surg Med; 2017 Dec; 49(10):882-885. PubMed ID: 28881431
[TBL] [Abstract][Full Text] [Related]
37. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
Simon JA; Goldstein I; Kim NN; Davis SR; Kellogg-Spadt S; Lowenstein L; Pinkerton JV; Stuenkel CA; Traish AM; Archer DF; Bachmann G; Goldstein AT; Nappi RE; Vignozzi L
Menopause; 2018 Jul; 25(7):837-847. PubMed ID: 29870471
[TBL] [Abstract][Full Text] [Related]
38. Treatment of dyspareunia secondary to vulvovaginal atrophy.
Fantasia HC
Nurs Womens Health; 2014; 18(3):237-41. PubMed ID: 24939201
[TBL] [Abstract][Full Text] [Related]
39. Use of a vaginal CO
Mejia-Gomez J; Bouteaud J; Philippopoulos E; Wolfman W; Brezden-Masley C
Climacteric; 2022 Jun; 25(3):228-234. PubMed ID: 34694948
[TBL] [Abstract][Full Text] [Related]
40. Profile of ospemifene in the breast.
Berga SL
Reprod Sci; 2013 Oct; 20(10):1130-6. PubMed ID: 23945733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
